Positive results from phase I clinical trial of SMT D002 for the treatment of Seborrhoea

SMT D002 suppresses sebum levels by 90% in repeat-dose trial

22-Apr-2008

Summit Corporation plc announced a positive outcome from its repeat-dose Phase I clinical trial of SMT D002, its candidate for the treatment of seborrhoea (excessive sebum production), a primary cause of acne.

The study was conducted in 18 healthy volunteers and examined the effect of repeat oral doses of SMT D002 over a four-day period. The key findings of the Phase I clinical trial are:

- Statistically significant levels of sebum suppression (primary endpoint) of 90% when compared to the placebo group (p=0.04)

- SMT D002 proved to be safe with no serious or unexpected adverse side-effects reported

- Sebum levels measured over six hours following treatment using a Sebumeter, an industry accepted method

- Results from trial support a previous positive Phase I single-dose study conducted in nine volunteers

The results of this trial confirm the potential of SMT D002 as a new therapeutic agent for the treatment of seborrhoea in acne patients. Summit plans to develop a topical formulation of SMT D002 to further evaluate its efficacy in the treatment of acne and the Company is actively seeking a commercial partner to advance this candidate from the clinic through to the market.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances